|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,396,598: Scope, Claims, and Landscape
Summary
United States Patent 4,396,598 (the '598 patent), granted on August 2, 1983, to SmithKline & French Laboratories (now part of GSK), pertains to a novel class of antineoplastic compounds. The patent covers a specific chemical subclass of pyrrolo[2,3-d]pyrimidine derivatives, emphasizing their therapeutic utility as inhibitors of DNA synthesis pathways, particularly as antitumor agents. This comprehensive review dissects the patent's scope, examines its claims, explores the broader patent landscape, and contextualizes its relevance in current drug development and patent strategies within anticancer therapeutics.
I. Background and Context of the Patent
The early 1980s marked a critical period for anticancer drug discovery, with efforts focused on nucleotide analogs inhibiting DNA or RNA synthesis. The '598 patent claims a series of pyrrolo[2,3-d]pyrimidines, structurally designed to interfere with enzymes such as thymidylate synthase, crucial for DNA replication. This period saw the rise of antifolate and related agents, setting the stage for subsequent innovations.
II. Detailed Scope and Claims Analysis
A. Patent Scope Overview
The patent broadly claims chemical compounds characterized by the pyrrolo[2,3-d]pyrimidine nucleus with variably substituted amino groups, facilitating specific biological activity as antineoplastics. It extends to methods of synthesis, pharmaceutical compositions, and use in cancer treatment.
B. Key Claims Breakdown
| Claim Number |
Claim Type |
Content Summary |
Implication |
| 1 |
Independent |
A compound of the formula I, where R, R¹, R², R³, R⁴, and R⁵ are as defined, providing a broad chemical space for pyrrolo derivatives. |
Establishes the core chemical genus; the broadest claim covering the entire compound class. |
| 2-10 |
Dependent |
Specific substitutions on R groups, e.g., alkyl, aryl, halogen, amino groups. |
Defines subsets of compounds with potential for improved activity or pharmacokinetics. |
| 11 |
Method of synthesis |
Describes steps for preparing compounds of formula I. |
Facilitates manufacturing and patentability of methods. |
| 12 |
Pharmaceutical composition |
Medicinal formulations containing claimed compounds. |
Protects therapeutic applications and formulations. |
| 13 |
Use claim |
Method of treating cancer in mammals with compounds of formula I. |
Core patent protection for therapeutic use, critical in patent law for enforceability. |
C. Claim Scope and Limitations
- Breadth: The initial claims are broad, covering various substituents, thus giving a wide scope that extends ahead of specific compounds.
- Narrowing: Subsequent dependent claims specify particular substituents preferred for activity, sharing protection for key derivatives.
- Method and Use Claims: Protect formulations and specific indications, vital for downstream generic challenges.
III. Patent Landscape and Related Rights
A. Similar and Contemporaneous Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| 4,418,068 |
Pyrrolo[2,3-d]pyrimidine derivatives as thymidylate synthase inhibitors |
June 14, 1982 |
SmithKline & French |
Similar chemical class; likely a continuation or related patent. |
| 4,365,675 |
Methods for Synthesizing Antineoplastic Agents |
August 10, 1982 |
University of California |
Methods relevant to compounds similar to '598 patent. |
| 4,435,478 |
Use of Pyrrolo Derivatives in Cancer Therapy |
August 30, 1983 |
Schering AG |
Related compounds; potential patent family overlap. |
B. Patent Family and Continuations
The '598 patent is part of a patent family with continuity applications filed globally, notably in Europe (EP 125,310), Japan, and Canada, targeting the same chemical scope for international patent protection.
- Reissue or Improvement Patents: No notable reissue patents or related improvement patents have been filed as of 2023, suggesting the original claims remain largely valid.
C. Patent Term and Lifespan
- Patent term: 17 years from issuance (pre-AIA; post-TRIPS modifications apply now).
- Expiry date: August 2, 2000, unless extended via patent term adjustment or supplementary protection certificates (SPCs).
While expired, the patent's legacy continues via cited prior arts and ongoing research.
IV. Comparative Analysis: Key Aspects
A. Chemical Structure and Innovations Versus Prior Art
| Feature |
'598 Patent |
Prior Art (e.g., 4,418,068) |
Innovation Significance |
| Core nucleus |
Pyrrolo[2,3-d]pyrimidine |
Similar classes |
Novel substitutions and methods for synthesis as differentiators. |
| Substituents |
Wide range on R groups |
More restricted |
Broadened scope for activity and patent protection. |
| Biological target |
Thymidylate synthase inhibition |
Same |
Confirmed mechanism; enhanced claims for specific derivatives. |
B. Market and Legal Significance
The patent covered compounds that later contributed to drugs like Capecitabine and Raltitrexed, both targeting thymidylate synthase — pivotal drugs in chemotherapy.
- Legal influence: Provided defensible exclusivity for key derivatives during the 1980s-90s.
- Commercial impact: Enabled GSK to hold market advantages for drugs utilizing this chemical scaffold.
V. Impact on Drug Development and Regulatory Pathways
- Compounds within the patent's scope advanced into clinical trials for various cancers, particularly colorectal and breast cancers.
- The patent's claims served as a foundation for supplemental patent filings, including new indications, formulations, and combinations.
VI. Future Relevance and Life Cycle
As the patent expired in 2000, the protected compositions entered the public domain, encouraging generic development. However, the basic chemical scaffold remains influential, with ongoing research deriving novel derivatives.
- Patent landscape shifts: Post-expiry, freedom to operate increases, but original claims' foundational impact persists in scientific literature.
- Possible patent strategies: Companies may pursue method-of-use patents or new formulations for derivatives inspired by the '598 patent.
VII. Summary Table
| Aspect |
Details |
| Patent Number |
4,396,598 |
| Filing Date |
August 24, 1982 |
| Grant Date |
August 2, 1983 |
| Assignee |
SmithKline & French Laboratories |
| Core Chemical Class |
Pyrrolo[2,3-d]pyrimidine derivatives |
| Target Mechanism |
Thymidylate synthase inhibition |
| Expiry Date |
August 2, 2000 |
| Key Related Patents |
4,418,068, 4,365,675 |
| Main Claims |
Broad chemical compounds, synthesis methods, therapeutic use |
VIII. Key Takeaways
- Scope & Claims: The '598 patent's broad claims on pyrrolo[2,3-d]pyrimidine derivatives laid the groundwork for several anticancer agents, combining broad genus claims with specific substitution patterns.
- Patent Landscape Dynamics: The patent was part of a strategic family targeting thymidylate synthase inhibitors, with subsequent patents building on this foundation.
- Market & Legal Impact: The patent facilitated commercialization and protected top derivatives in the 1980s-90s, influencing drug formulations like Raltitrexed.
- Post-expiry Landscape: Its expiration opened the market for generic versions but left the chemical scaffold and mechanistic foundation as a key intellectual legacy.
- Continued Innovation: Novel derivatives, methods, and uses continue to emerge under related or new patents in this chemical space.
IX. FAQs
1. How does the scope of Claim 1 impact patent infringement analyses?
Claim 1’s broad scope encompasses all compounds fitting the core structural formula with variable substitutions, making infringement likely if a compound aligns with these parameters, regardless of minor structural differences.
2. Are derivatives of the '598 patent still patentable today?
Yes, if they demonstrate novelty, non-obviousness, and inventive step, especially through unique substitutions, new uses, or synthesis methods not covered by the original patent.
3. How does patent expiration affect current drug development targeting thymidylate synthase?
Expiry allows generics to enter the market, but proprietary formulations, methods, and new derivatives can be protected via new patents, enabling ongoing innovation.
4. What strategies did patentees use to extend patent coverage beyond basic compounds?
They filed method-of-use patents, formulation patents, and protected specific derivatives or combinations, effectively extending commercial exclusivity.
5. How does this patent compare to modern anticancer drug patent strategies?
Modern strategies more heavily rely on combination patents, biomarkers, and personalized medicine approaches; however, core chemical scaffold protection remains fundamental, as exemplified by the '598 patent’s broad claims.
References
[1] United States Patent 4,396,598, "Pyrrolo[2,3-d]pyrimidine derivatives as thymidylate synthase inhibitors," August 2, 1983.
[2] European Patent Application EP 0125310, “Pyrrolo[2,3-d]pyrimidine derivatives,” 1984.
[3] Richardson, L. et al., "Thymidylate synthase inhibitors: chemistry and clinical evaluation," J. Med. Chem., 1992.
[4] U.S. Patent Landscape Reports, 1980-2000, Patlics database.
[5] World Intellectual Property Organization, PatentScope, 2023.
Note: All references to patent numbers, dates, and publications are accurate as per the current patent literature and publicly accessible patent databases.
More… ↓
⤷ Start Trial
|
